This trial is active, not recruiting.

Condition hepatic veno-occlusive disease
Treatments defibrotide
Phase phase 3
Sponsor Jazz Pharmaceuticals
Start date December 2007
End date July 2016
Trial size 1211 participants
Trial identifier NCT00628498, P2006-05


Single arm, open-label study to provide Defibrotide to patients diagnosed with VOD. Defibrotide is no longer available though the Emergency Use IND mechanism (also known as compassionate use, or single patient named use). This protocol is the only mechanism by which Defibrotide can be made available to patients in the U.S.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Defibrotide 25 mg/kg day given in 4 divided doses approximately every 6 hours
Defibrotide is a single-stranded polydeoxyribonucleotide derived from porcine intestinal mucosa by controlled depolymerisation. Defibrotide has a complex mechanism of action with antithrombotic, anti-ischemic, anti-inflammatory, anti-adhesive and thrombolytic properties but no significant systemic anti-coagulant effects. Defibrotide is dose intravenously as a 2-hour infusion every 6 hours at a dose of 25 mg/kg/day. Recommended duration of therapy is 21 days.

Primary Outcomes

Survival at Day +100 or from HSCT or 100 days from start of chemotherapy
time frame: Day +100 from HSCT or 100 days from start of chemotherapy

Secondary Outcomes

Tolerability & Safety Data from Patients with VOD
time frame: From time of Consent to 30 Days Post of Last Administration of Study Drug

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: Entry criteria include the following: 1. Clinical diagnosis of VOD, made by Baltimore Criteria, Modified Seattle Criteria, or biopsy proven: 1.1 Baltimore Criteria- Bilirubin ≥2 mg/dL and at least 2 of the following clinical findings: - Ascites (radiographic or physical exam) - Weight gain of ≥5% compared to the day of conditioning-- if this value is not available, the weight on the date of admission to the SCT unit may be used) - Hepatomegaly; increased over baseline. 1.2 Modified Seattle Criteria: At least two of the following - Bilirubin ≥2 mg/dL - Ascites (radiographic or physical exam) and/or weight gain ≥5% above baseline weight (defined as weight on the first day of conditioning- if this value is not available, the weight on the date of admission to the SCT unit may be used) - hepatomegaly increased over baseline 1.3 Patients that do not meet the Baltimore Criteria or Modified Seattle Criteria and have biopsy proven VOD are eligible. 2. Patient must also provide written informed consent. Exclusion Criteria: - Use of any medication which increases the risk of hemorrhage is disallowed. Use of heparin or other anticoagulants is disallowed within 12 hours unless being used for routine central venous line management, fibrinolytic instillation for central venous line occlusion, intermittent dialysis or ultrafiltration of CVVH. - Clinically significant uncontrolled acute bleeding, defined as hemorrhage requiring > 15 cc/kg of packed red blood cells (e.g., a pediatric patient weighing 20 kg and requiring > 300cc of packed red blood cells/24 hours, or an adult patient weighing 70 kg and requiring >3 units of packed red blood cells/24 hours) to replace blood loss, OR bleeding from a site which in the Investigator's opinion constitutes a potential life-threatening source (e.g. pulmonary hemorrhage or CNS bleeding), irrespective of amount of blood loss, at any point from the date of SCT through the date of severe VOD diagnosis. - Hemodynamic instability as defined by a requirement for multiple pressors, or inability to maintain mean arterial pressure (for children: to maintain mean arterial pressure within 1 standard deviation of age-adjusted levels) with single pressor support. - Woman who are pregnant.

Additional Information

Official title Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Principal investigator Paul Richardson, M.D.
Trial information was received from ClinicalTrials.gov and was last updated in June 2016.
Information provided to ClinicalTrials.gov by Jazz Pharmaceuticals.
Location data was received from the National Cancer Institute and was last updated in September 2016.